The COVID-19 outbreak due to the novel SARS-CoV-2 virus has turned into a global pandemic infecting hundred thousands of people worldwide. With a rapid rate of infection and a high mortality rate, it is estimated that the novel COVID-19 can infect millions of people all over the globe. Quick intervention at this stage to curb further spread becomes crucial and can only be achieved through expediting critical life science research. Scientists and clinicians around the world are focusing on understanding the molecular biology and mechanisms adapted by COVID-19, and its lethal mode of action. To understand the virus completely and develop safe therapeutic interventions, scientists require a range of trusted molecular biology reagents such as high-quality recombinant proteins related to SARS-CoV-2.
SignalChem, a global leader in cell signaling and protein engineering, has been devoting resources in creating and developing new research tools related to SARS-CoV-2 virus since the outbreak. With the help of advanced bioengineering technology to produce active proteins and AI drug development capability, we have already established expression systems for production of SARS-CoV-2 Spike proteins, RBD fragments, N protein, and other related protein products on a large scale to help detect IgG / IgM in potential patients. These proteins can be used as diagnostic standard antigens and can serve as targets of neutralizing antibodies under development and can also be used by scientists in their development of antibodies to detect SARS-CoV-2 virus in patients. In addition, SignalChem uses mammalian and insect cell expression systems in its production of these protein products as this is more immunogenic than the protein expressed from the E. coli system.